Carcinoma in situ of anus and anal canal
ICD-10 D01.3 is a billable code used to indicate a diagnosis of carcinoma in situ of anus and anal canal.
Carcinoma in situ of the anus and anal canal refers to a localized form of cancer where abnormal cells are present in the epithelial layer of the anal canal or anus but have not invaded deeper tissues. This condition is often asymptomatic in its early stages and may be discovered during routine examinations or screenings. Risk factors include human papillomavirus (HPV) infection, immunosuppression, and a history of anal warts. Surveillance protocols typically involve regular anal Pap smears and high-resolution anoscopy to monitor for progression to invasive cancer. The prognosis for carcinoma in situ is generally favorable, but there is a risk of progression to invasive carcinoma, particularly in high-risk populations. Early detection and intervention are crucial for effective management and improved outcomes.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis of carcinoma in situ during routine screening, management of HPV-related lesions.
Ensure accurate staging and documentation of any treatments or interventions.
Endoscopy reports, biopsy results, and patient history.
Surveillance colonoscopy findings, management of anal dysplasia.
Document any findings related to anal canal lesions and follow-up recommendations.
Used when a biopsy is performed to confirm carcinoma in situ.
Pathology report confirming diagnosis and procedure notes.
Oncologists and gastroenterologists should ensure clear documentation of findings.
Carcinoma in situ is a critical early stage of cancer that, if left untreated, can progress to invasive cancer. Early detection and management are essential for favorable outcomes.
